Human NeuNAc-9-P synthase is a two-domain protein with ability to synthesize both NeuNAc-9-P and KDN-9-P. Its mouse counterpart differs by only 20 out of 359 amino acids but does not produce KDN-9-P. By replacing the AFL domain of the human NeuNAc-9-P synthase which accommodates 12 of these differences, with the mouse AFL domain we examined its importance for the secondary KDN-9-P synthetic activity. The chimeric protein retained almost half of the ability of the human enzyme for KDN-9-P synthesis while the NeuNAc-9-P production was reduced to less than 10%. Data from the homology modeling and the effect of divalent ions and temperature on the enzyme activities suggest conformational differences between the human and mouse AFL domains that alter the shape of the cavity accommodating the substrates. Therefore, although the AFL domain itself does not define the ability of the human enzyme for KDN-9-P synthesis, it is important for both activities by aiding optimal positioning of the substrates. 
INTRODUCTION
Sialic acids (SA) form a diverse family (more than 50 members) of negatively charged 3-deoxy-2-keto nine-carbon sugars and have been found to play a role in many cellular events (1) . As a result, a number of research groups have focused efforts towards the discovery, structural determination, and mechanistic elucidation of the enzymes responsible for SA synthesis.
In prokaryotes, the final stage of formation of N-acetyl-D-neuraminic acid (NeuNAc) the most common sialic acid in nature involves condensation of N-Acetyl-D-mannosamine (ManNAc) with phosphoenol pyruvate (PEP). The process, when irreversible, is catalyzed by the enzyme NeuNAc synthase (E.C. 4.1.3.19). The first bacterial gene, neuB gene, coding for the E. coli enzyme was identified in 1995 (2) and this later allowed overexpression and purification of sufficient amount of protein for detailed characterization (3) . Using the E. coli neuB coding sequence to query the Human Genome Sciences cDNA database with the BLAST algorithm (4) discovered the first mammalian (human) ortholog. Applying a similar approach (5) cloned the Mus musculus neuB gene.
Bacterial and vertebrate neuB genes code for enzymes that have similar sizes of 346-359 amino acids (AA), share 30-36% identity and show similar architectures. Two distinct domains comprise the neuB gene products. The catalytic domain (TIM barrel domain) positioned N-terminally consists of ~270 AA and folds as a typical triose-phosphate isomerase (beta/alpha) 8 barrel (6) . A linker of 11 AA connects it to a smaller, ~75 AA antifreeze-like domain (AFL domain), the name indicating its similarity to type III antifreeze proteins (7) . Bacterial and mammalian enzymes function as homodimers with a unique domain-swapped architecture. Once the substrate enters the binding pocket of the TIM barrel domain, the AFL domain of the opposite monomer caps the cavity (6). However, a significant difference is that the mammalian ortholog, NeuNAc phosphate synthase (E.C. 2.5.1.57) shows strong preference toward phosphorylated ManNAc ManNAc-6-P (4, 5, 8) , and therefore the final product of the reaction after condensation with PEP is NeuNAc-9-P. Additionally, human NeuNAc phosphate synthase was found to possess 2-keto-3-deoxy-D-glycero-D-galacto-nonulosonic acid-9-P (KDN-9-P) synthetic activity (4). Contrarily, the mouse protein cannot produce deaminated NeuNAc at the level of fluorescent detection after 1,2-diamino-4,5-methylenedioxybenzene derivatization coupled with http://bmbreports.org BMB reports HPLC separation (5) . Likewise, when (8) purified and analyzed NeuNAc-9-P synthase from rat liver, they were not able to demonstrate KDN-9-P synthetic activity. Human NeuNAc-9-P synthase shares 94-95% identity at the AA level with its mouse and rat counterparts; the last two are 97% identical with each other. Recently (9) reported that replacement of methionine at position 42 of the TIM barrel domain with any AA except leucine abolishes the KDN-9-P synthetic activity of human protein while maintaining the NeuNAc-9-P activity at levels on par with the wild-type enzyme. Previously, Baardsnes and Davies in 2001 (7) discovered the striking resemblance of the C-terminal region of mammalian NeuNAc-9-P synthases to the fish type III antifreeze proteins and suggested a hypothesis about the involvement of this domain in substrate binding. Noticeably, ~65% of the differences between the human and mouse/rat enzymes are located in the AFL domain which is four times smaller than the TIM barrel domain. Therefore, it is logical to examine the importance of the AFL domain in relation to NeuNAc-9-P synthase substrate specificity. The current work describes the replacement of AFL domain of human NeuNAc-9-P synthase with that of the mouse and the activity of the resultant chimeric enzyme.
RESULTS

In silico analyses of mammalian NeuNAc-9-P synthases
Mammalian NeuNAc-9-P synthases are highly conserved 359 AA proteins. Overall, the human NeuNAc-9-P synthase shows 94.4% identity with the mouse and 94.7% identity with the rat NeuNAc-9-P synthase, these numbers reflecting 20 and 19 AA differences, respectively (Fig. 1) . The identity between human/mouse and human/rat enzymes outside of the AFL domain (1-288 AA) is 97.2% in both cases; however, within the AFL domain (289-359AA) the identity is only 83.1% -12 AA differences, and 84.5% -11 AA differences, respectively. Ten of these differences are identical for mouse and rat NeuNAc-9-P synthases compared to the human enzyme. Overall, mouse AFL domain stability is comparable to that of the human AFL domain the free energy difference calculated by FOLD-X (13) is ΔΔG = 3.96 kcal/mol.
A homology model of the mouse AFL domain was built on the basis of the three-dimensional structure of the human AFL domain resolved by NMR spectroscopy (10) . The structure of the human AFL domain is comprised of one alpha-helix (Met309-Met311), two single-turn 3 (10)-helices (Ile327-Leu330, Glu347-Leu349), and two beta-strands (Ser294-Ala297 and Leu312-Lys315) (10) . The mouse AFL domain lacks both 3 (10)-helices (Fig. 2iv ). This is due to the fact that Met309 and Leu349 of human AFL domain amino acids with very high helix-forming propensities are replaced with Thr309 and Ser349, respectively, in the mouse AFL domain. Most of the amino acids that differ between human and mouse AFL domains are clustered on the b face (Glu/Ala303, Ile/ Thr306, Asp/Glu351, Asn/Ser352, Gly/Ser354 and Ser/ Ala359). Only two of the differences (Met/Leu309 and Leu/ Ser349) are visible on the d face a substrate-binding surface for the bacterial NeuNAc synthases (Fig. 2ii ). There is redistribution of the positive and negative surface charges, however without drastic changes in the hydrophobicity (Fig. 2i, iii) .
Purification and activity of human and chimeric NeuNAc-9-P synthases
Chimeric NeuNAc-9-P synthase, containing the human TIM barrel domain and the mouse AFL domain was engineered by five sequential cycles of site-directed mutagenesis. To overcome the poor solubility after native expression, the chimeric and the human enzymes were expressed as fusions with GST by transferring the genes to pDEST15. In both cases, addition of 2% Triton-X 100 to the extraction buffer was able to ensure solubilization of significant part of the produced recombinant proteins after induction overnight at 25 o C and sufficient yield after purification on Glutathione-Agarose. After thrombin cleavage and another round of Glutathione-Agarose chromatog-http://bmbreports.org o rotation about the Y-axis (see lower right) and represents the a-d faces of the domains: (i) the AFL domains' electrostatic surface potential (240 points per atom) with underlying secondary structures -positive charges are blue, negative charges are red; (ii) solvent accessible surface (1.4Å) of the domains -the residues different between the human and mouse AFL domains are highlighted in green (classconserved), or orange (non-conserved); mutation N353Q is buried within the structure; (iii) electrostatic surface potential of the d-face shown in detail; the lysine residues (K298 and K315) potentially interacting with ManNAc-6-P are depicted; (iv) ribbon diagrams of the human and mouse AFL domains: alpha-and 3(10)-helices and beta-strands are colored red, pink, and blue, respectively.
raphy to remove the GST and the uncleaved protein, both human and chimeric enzymes were detected as a single ~43 kDa band on SDS polyacrylamide gels (Fig. 3A) . The apparent molecular mass of the purified proteins was ~82 kDa as estimated by gel filtration chromatography on Sephadex G 100 (Fig. 3B) suggesting that similar to the rat NeuNAc-9-P synthase (8) they also form dimers.
The specific NeuNAc-9-P and KDN-9-P synthetic activities of the human enzyme determined in the presence of 12.5 mM MnCl2, 8.3 mM PEP and 2.5 mM ManNAc-6-P or 12.5 mM Man-6-P as a substrate, were 11.7 mU/mg protein and 0.22 mU/mg protein respectively. Replacement of the human AFL domain with the mouse one resulted in significant loss (~92%) of Neu5Ac-9-P synthase activity; the ability for production of KDN-9-P decreased as well, but to a lower extent the chimeric enzyme retained 55% of the activity of human one (Fig. 3C ).
Thermostability and effect of divalent ions on the activity of human and chimeric NeuNAc-9-P synthases
Exposure at 37 o C or 55 o C for 10 min resulted in comparable retention of the initial ability of human and chimeric NeuNAc-9-P synthases for production of NeuNAc-9-P. Under these conditions the chimeric enzyme lost 71% of its initial KDN-9-P synthetic activity, while that of the human one was only 43% lower. Treatment for 10 min at 65 o C resulted in retention of 26% and 39% of NeuNAc-9-P and KDN-9-P activity, respectively, of the human enzyme. Under these conditions, the chimeric enzyme kept 17% of its initial NeuNAc-9-P activity while completely losing its ability for KDN-9-P production. Opposite to the human NeuNAc-9-P synthase, the KDN-9-P synthetic activity of the chimeric protein was less resistant to high temperatures than its NeuNAc-9-P synthetic activity (Fig. 3D) .
Both NeuNAc-9-P and KDN-9-P synthetic activities of the human enzyme were favored by the presence of Mn 2+ ions at a concentration of 12.5 mM. At the same concentration, Mg 2+ ions decreased the ability for NeuNAc-9-P synthesis by almost half, while the KDN-9-P synthetic activity dropped by 20% only. Similar to the human enzyme, the NeuNAc-9-P synthetic activity of the chimeric protein showed higher values in the presence of Mn 2+ ions, but they were less effective for KDN-9-P synthase activity in comparison with Mg 2+ ions (Fig. 3C ).
DISCUSSION
The crystal structure of N. meningitidis NeuNAc synthase in complex with Mn
2+
, PEP and N-acetylmannosaminitol revealed that although the active site of the enzyme is located in a deep depression at the C-terminal end of the TIM barrel, the AFL domain of the opposite neuB monomer also plays a direct role in substrate binding, and thus also works to define the optimal substrate structures (6) . By engineering a chimeric enzyme consisting of the TIM barrel domain of human NeuNAc-9-P synthase and the AFL domain of mouse NeuNAc-9-P synthase, we showed that it is not the difference between the AFL domains of these two proteins that determines the extra activity of the human enzyme towards Man-6-P, as the chimeric protein still has the ability to synthesize KDN-9-P. Thus, it appears that only one residue Met42 of the human TIM barrel domain, although far away from the active site or dimer inter-http://bmbreports.org BMB reports Fig. 3 . (A) Monitoring the purification of human and chimeric NeuNAc-9-P synthases. SDS PAGE (4-20% gradient gel) of total proteins (t), purified by chromatography on Glutathione-Agarose human and chimeric NeuNAc-9-P synthase-GST fusion proteins (p) and cleaved from the GST tag and purified human and chimeric NeuNAc-9-P synthases (pc) isolated from non-induced (NI) and induced with 0.2% arabinose (I) E. coli harboring pDEST15:SAPShuman or pDEST15:SAPSchimeric vector. Staining Coomassie Brilliant Blue R-250. Position and molecular mass (kDa) of the markers (BioRad Kaleidoscope) are shown on the right; (B) Gel filtration chromatography of the purified human (▾) and chimeric (•) NeuNAc-9-P synthase; (C) Comparison between the relative NeuNAc-9-P and KDN-9-P synthetic activities and the effect of Mg 2+ and Mn 2+ ions. Human enzyme activities (11.7 mU/mg protein NeuNAc-9-P synthetic activity; 0.22 mU/mg protein KDN-9-P synthetic activity) were used as a reference to normalize the activities of the chimeric enzyme. Data are mean ± SD (n = 4; P = 0.05); (D) Effect of temperature on the enzyme activities of the human and chimeric NeuNAc-9-P synthases the enzyme solutions were pretreated for 10 min at the specified temperatures before being used for the enzyme assay. The highest activity in each case was used to normalize. Data are mean (n = 4; P = 0.05), SDs were less than 12%.
face, is essential for the secondary KDN-9-P synthase activity of human NeuNAc-9-P synthase (9) .
The role of the AFL domain in mammalian enzymes, as in bacterial ones, is far from being merely a passive cap that seals the active site. This is evident from the fact that the chimeric NeuNAc-9-P synthase shows an altered ability for both KDN-9-P and NeuNAc-9-P production. The homology model presented in this paper predicts overall conformational changes in the mouse AFL domain from the human one including changes to the surface of the d face, which faces the depressed cavity of the TIM barrel in bacterial enzymes (6) . The effects of divalent ions on the activities of human and chimeric NeuNAc-9-P synthases offer indirect evidence for the altered shape of this cavity. Mg 2+ ions that are slightly smaller and prefer six-coordinated complexation geometry favor the KDN-9-P synthetic activity of the chimeric enzyme, while the same activity of the human enzyme is higher in the presence of Mn 2+ ions that coordinate octahedrally.
In particular, Arg314 of AFL domain of bacterial NeuNAc synthase is extremely important for sugar substrate recognition and binding (6, 11) . Mammalian NeuNAc-9-P synthases lack this arginine residue, however, as noticed from the NMR-re-http://bmbreports.org solved 3-D structure of human AFL domain, two other AA with positively charged side chains, Lys298 and Lys315, have similar topology (10) , and although both of these lysines are conserved in the vertebrate AFL domain subfamily (10), their positions in the human versus mouse AFL domain are not exactly the same as evident by our results from the homology modeling. Assuming that the lysine residues in mammalian enzymes play the same role as Arg314 of the N. meningitidis protein, subtle differences in their topology might have profound effects on the enzyme activity. Arg314 in bacterial NeuNAc synthase is involved in forming hydrogen bonds with O4 and O7 (acetyl group oxygen) of N-acetylmannosaminitol (6). Man-6-P lacks an acetyl group, which makes this substrate less dependent on fluctuations in the positioning of the Arg314-corresponding Lys298 and Lys315 residues. This might explain the relatively high residual KDN-9-P synthetic activity of the chimeric enzyme, while its NeuNAc-9-P activity was greatly reduced. Altered enzyme stability could also be considered as a possible factor for the observed changes in the activity -although the chimeric protein retained the ability to form dimers, its yield after purification was consistently lower (by ~30%) compared to that of the human enzyme. Its thermal stability was also decreased, but the better preserved KDN-9-P synthetic activity was more sensitive to higher temperatures.
In conclusion, the presented work shows that the AFL domain of mammalian NeuNAc-9-P synthases is important for their enzyme activity possibly by ensuring optimal positioning of the sugar substrate. This small domain could be a good target for directed evolution experiments with the aim of engineering an enzyme with a primary KDN-9-P synthetic activity.
MATERIALS AND METHODS
Computational analyses
Protein sequences were aligned with ClustalW 1.8 (12) . The Gibbs free energy of folding of human and mouse AFL domains were predicted with FOLD-X (http://fold-x.embl-heidelberg.de:1100/cgi-bin/main.cgi, (13)). A homology model of the mouse AFL domain was built based on the 3D structure of the AFL domain of human NeuNAc-9-P synthase ((10), PDB code 1WVOA) with the program MODELLER version 9.1 using default parameters. The model was verified with PROCHECK-NMR (14, 15) . Accelrys DS version 7.1 (Accelrys, http://www. accelrys.com/) was used to compute solvent accessibility at 1.4 Å and surface potential with 240 points per atom with hydrogens removed and to visualize the structures.
Vector construction
The full-length cDNA coding for H. sapiens NeuNAc-9-P synthase (GenBank Accession No AF257466.1) was amplified by SAPS1 (5'-CACCATGCCGCTGGAGCTGGAGCTGTGTC-3')/SAPS2 (5'-CCTTTAAGACTTGATTTTTTTGCCATGATTATCTACC-3') pair of primers using Pfu Turbo DNA polymerase (Stratagene) and the following program: initial denaturation for 5 min at Replacement of the AFL domain of the human enzyme with the AFL domain of the mouse NeuNAc-9-P synthase (GenBank Accession No NM_053179) was accomplished by five rounds of site-directed mutagenesis (Stratagene QuikChange Multi Site-Directed Mutagenesis Kit, Stratagene) using the following primers: first round AFL1 (5'-GTGAAAATTCCGGCAGGCA-CCACTCTAACATTGGACATGCTCACC-3' for E303A, I306T, M309L), AFL2 (5'-GTGAAGGTGGGTGAGCCCAAAGGCTAT-CCTCCTGAAGAC-3' for A321G), AFL3 (5'-ATCTTTAATCTA-GCGGGCAAGAAGGTCCTGGTCACTGTTGAAGAG-3' for V-331A), AFL4 (5'-GTAGATAATCATAGCAAAAAAATCAAGTC-TTAAAAGGGTGGGCGCGCCG-3' for G354S); second round AFL5 (5-GGTCCTGGTCACTATTGAAGAGGATGACACCGT-CATGGAAGAATCGGTAGATAATCATGGC-3' for V339I, I345V and L349S); third round AFL6 (5-GAGGATGACACCGTCAT-GGAAGAATCGGTAGATAGTCATGGC-3' for N352S); fourth round AFL7 (5'-GGAAGAATCGGTAGATAGTCATAGCAAA-AAAATCAAGGCTTAAAAGGGTCG-3' for S359A), fifth round AFL8 (5'-GGATGACACCGTCATGGAAGAATTGGTAGAGA-GTCATAGC-3' for D351E). All clones were sequence-verified (Applied Biosystems 3730 Sequencer, DNA Laboratory at SOLS, ASU) before proceeding to the next round of mutagenesis. Human NeuNAc-9-P synthase and chimeric NeuNAc-9-P synthase genes were then transferred by Gateway LR Clonase Reaction to pDEST17 (Invitrogen) for native expression in E. coli, but problems with solubility of the recombinant proteins were encountered. To overcome them, both human and chimeric enzymes were expressed as fusion proteins the genes were positioned after the 3' end of glutathione S-transferase (GST) gene provided by pDEST15 expression vector (Invitrogen). A thrombin cleavage site (LysValProArgGlySer) between GST and human/chimeric NeuNAc-9-P synthase was introduced by site-directed mutagenesis using primer SAPS3 (5'-CCTCCAAAATCG-GATCTGGTTCCGCGTGGATCATCGAATCAAACAAG-3').
Expression, extraction and purification of recombinant proteins
Both pDEST15:SAPShuman and pDEST15:SAPSchimeric were transferred to E. coli BL21-AI chemically competent cells (Invitrogen) and selected in the presence of 100 mg/l ampicillin. Transformed cells were grown to OD600 of 0.6, and recombinant protein production was induced by 0.2% (w/v) arabinose in overnight incubation at 25 o C. The cells were harvested by centrifugation (10,000 g/10 min/4 o C), resuspended in PBS buffer pH 7.4 supplemented with 2 mM DTT, 1 mM PMSF, 10 U/ml DNAse, 1 mM MgCl2, 0.2 mg/ml lysozyme, and 2% (v/v) Triton X-100 (Molecular Probes) and incubated for 30 min on ice. After three freeze/thaw cycles and sonication, the lysate was spun down at 13,000 g for 15 min at http://bmbreports.org BMB reports 4 o C. Recombinant proteins were further purified by chromatography on Glutathione Agarose (Molecular Probes) and subjected to thrombin cleavage according to manufacturer's specifications (Amersham Biosciences). The samples were dialyzed against 50 mM Tris HCl pH 8.0 at 4 o C (MWCO 3000 Da) and a second round of Glutathione Agarose chromatography was performed to remove the free GST and the remaining uncleaved fusion protein. The process of purification was monitored using SDS-PAGE (16) .
The molecular mass of the purified human and chimeric enzymes was determined by gel filtration chromatography on Sephadex G 100 column (50 cm × 0.8 cm i.d.) equilibrated with 25 mM phosphate buffer pH 7.4 containing 50 mM NaCl and 5 mM MgCl2. The column was calibrated with bovine serum albumin (66 kDa), ovalbumin (45 kDa) and myoglobin (17 kDa). Fractions of 0.42 ml were collected throughout at a flow rate of 0.085 ml/min.
Enzyme assay
KDN-9-P and NeuNAc-9-P synthetic activities of human and chimeric enzyme were assayed as described (4, 9) . Briefly, 100 μl of the substrate solution (25 mM Man-6-P or 5 mM ManNAc-6-P, 25 mM MnCl2, and 16.6 mM PEP in 50 mM Tris HCl buffer pH 8.0) were added to 100 μl of enzyme solution. The reactions were carried out at 37 o C and stopped by boiling for 5 min. After centrifugation for 5 min at 13,000 rpm, the samples were analyzed by TBA assay (17, 18) . The enzyme activity was calculated using molar absorption coefficient for NeuNAc of 57,000 M 1 ㆍcm 1 at 549 nm and for KDN of 56,000 M 1 ㆍcm 1 at 549 nm (18) . Chimeric and human enzyme solutions boiled for 10 min and centrifuged for 5 min at 13,000 rpm before performing the enzyme reaction were used to set up controls. One unit of enzyme activity was defined as the amount of the enzyme that synthesizes 1 μmol product per 1 min under the conditions described above.
Thermostability and metal ion requirement studies
The effect of temperature on stability of human NeuNAc-9-P synthase and chimeric NeuNAc-9-P synthase was monitored by incubating the enzyme solution at C, or in a boiling water bath for 10 min before performing the enzyme assay as described above. For studying the effect of divalent ions on the activity, the buffer of the enzyme solution was exchanged to 50 mM Tris-HCl pH 8.0 (Amersham PD10 columns), and the substrate solution was supplemented with 25 mM MnCl2, or 25 mM MgCl2. The enzyme assay was performed as described above.
